yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
norditropin nordiflex 10 mg/1,5 ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
somatropin - raztopina za injiciranje v napolnjenem injekcijskem peresniku - somatropin 10 mg / 1,5 ml - somatropin
norditropin nordiflex 15 mg/1,5 ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
somatropin - raztopina za injiciranje v napolnjenem injekcijskem peresniku - somatropin 15 mg / 1,5 ml - somatropin
norditropin nordiflex 5 mg/1,5 ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
somatropin - raztopina za injiciranje v napolnjenem injekcijskem peresniku - somatropin 5 mg / 1,5 ml - somatropin